Key Performance
More- Earnings Score: N/A
- Momentum Score: 18
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
A class action lawsuit has been filed against Fractyl Health, Inc. for allegedly making materially false and misleading statements regarding its Revita product's effectiveness and clinical trial integrity during the period between January 13, 2025 and January 29, 2026. Investors who suffered losses are urged to contact the law firm by October 20, 2026 to participate in the action.
10/01/2026, 5:28 PM • GlobeNewswire
Law Offices of Howard G. Smith has announced securities fraud class action lawsuits against four publicly-traded companies: Flotek Industries, Aevex Corp, Fractyl Health, and GoDaddy Inc. The lawsuits allege materially false and misleading statements regarding business operations and prospects. Investors have until October 2026 to file lead plaintiff motions.
09/24/2026, 4:00 PM • GlobeNewswire
A class action lawsuit has been filed against Fractyl Health, Inc. (NASDAQ: GUTS) alleging that company executives made materially false and misleading statements about the effectiveness of its Revita product and the integrity of REMAIN-1 clinical trial results. Investors who purchased Fractyl securities between January 13, 2025 and January 29, 2026 may be eligible to join the lawsuit, with a lead plaintiff deadline of October 20, 2026.
09/24/2026, 1:00 PM • GlobeNewswire
Robbins LLP announced a class action lawsuit against Fractyl Health, Inc. (NASDAQ: GUTS) for allegedly misleading investors about the efficacy of its Revita DMR System. The company's stock plummeted 68% on January 29, 2026, after disclosing disappointing six-month clinical trial data that fell short of investor expectations. The lawsuit covers investors who purchased securities between January 13, 2025 and January 29, 2026.
09/23/2026, 7:48 PM • GlobeNewswire
Pomerantz LLP filed a class action lawsuit against Fractyl Health, Inc. (NASDAQ: GUTS) for alleged securities fraud. The lawsuit claims defendants made materially false statements about the efficacy of Revita, their diabetes and obesity treatment device. On January 29, 2026, Fractyl disclosed disappointing six-month data from the REMAIN-1 Midpoint Cohort showing only 4.5% weight regain versus 7.5% in the sham arm, and revealed operational issues at one clinical site. The stock price fell 68.03% following the disclosure. The class period covers purchases between January 13, 2025 and January 29, 2026.
09/22/2026, 4:50 PM • GlobeNewswire
Fractyl Health (GUTS) faces a class action securities fraud lawsuit after disclosing disappointing six-month efficacy data for its Revita treatment on January 29, 2026. The company's weight loss results (4.5% regain vs. 7.5% in control) fell significantly short of investor expectations, causing the stock to plummet 68% to $0.58 per share. Shareholders are urged to file lead plaintiff motions by October 20, 2026, with allegations that defendants made materially false statements about Revita's effectiveness and clinical prospects.
09/22/2026, 2:50 PM • GlobeNewswire
A class action lawsuit has been filed against Fractyl Health, Inc. (NASDAQ: GUTS) alleging that company executives made materially false and misleading statements regarding the effectiveness of its Revita product and the integrity of clinical trial results. The lawsuit covers investors who purchased Fractyl securities between January 13, 2025 and January 29, 2026. The lead plaintiff deadline is October 20, 2026.
09/22/2026, 12:00 PM • GlobeNewswire
A class action lawsuit has been filed against Fractyl Health, Inc. (NASDAQ: GUTS) alleging that company executives made materially false and misleading statements about the effectiveness of its Revita product and the integrity of clinical trial results during the period from January 13, 2025 to January 29, 2026. Investors who purchased Fractyl securities during this period are encouraged to join the lawsuit, with a lead plaintiff deadline of October 20, 2026.
09/03/2026, 12:00 PM • GlobeNewswire
A class action lawsuit has been filed against Fractyl Health, Inc. (NASDAQ: GUTS) alleging that company defendants made materially false and misleading statements regarding Revita's effectiveness and clinical trial integrity during the period from January 13, 2025 to January 29, 2026. Investors who purchased Fractyl securities during this period are encouraged to join the case, with a lead plaintiff deadline of October 20, 2026.
09/01/2026, 12:00 PM • GlobeNewswire
Shareholder class action lawsuits have been filed against GoDaddy Inc., Taboola.com Ltd., and Fractyl Health, Inc., alleging false and misleading statements regarding business practices. Investors who purchased shares during specified periods and experienced losses are encouraged to contact legal counsel. The lead plaintiff deadline is October 20, 2026.
08/26/2026, 7:00 AM • GlobeNewswire
Shareholder class action lawsuits have been filed against Taboola.com Ltd., GoDaddy Inc., and Fractyl Health, Inc., alleging that defendants made false and misleading statements about their business operations. Taboola is specifically accused of overstating publisher relationship values due to increased low-quality publishers. The lead plaintiff deadline for all cases is October 20, 2026.
08/26/2026, 7:00 AM • GlobeNewswire
Shareholder class action lawsuits have been filed against Fractyl Health, GoDaddy, and Taboola, alleging that defendants made false and misleading statements or failed to disclose material adverse facts. The lead plaintiff deadline for all cases is October 20, 2026. Investors who purchased shares during specified periods and experienced losses are encouraged to contact the law firm.
08/26/2026, 7:00 AM • GlobeNewswire
Scalable Biotech Manufacturing Unlocks a $14B Market
The global cell therapy manufacturing market is projected to reach $14 billion by 2035, driven by over 1,000 active clinical candidates. FDA regulatory flexibility is accelerating timelines for cell and gene therapy approvals. Several biotech companies are advancing scalable manufacturing capabilities and clinical programs: Avaà Bio is producing Master Cell Banks for α-Klotho therapy; ImmunityBio validated scalable NK cell manufacturing; Fate Therapeutics achieved outpatient CAR T-cell therapy for autoimmune diseases; Fractyl Health completed pivotal trial randomization for GLP-1 weight maintenance; and Moleculin Biotech enrolled its 45th subject in a Phase 2B/3 AML trial.
03/27/2026, 9:15 AM • Benzinga
Fractyl Health will call its outstanding Tranche A Common Stock Purchase Warrants, allowing holders to exercise at $1.05 per share until December 30, 2025, potentially raising $17.9 million in gross proceeds.
12/15/2025, 5:45 PM • GlobeNewswire
Fractyl Health reported positive 6-month clinical results showing patients maintained stable weight after a single Revita procedure following GLP-1 drug discontinuation, with minimal weight change and promising metabolic control.
12/02/2025, 7:00 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 10/01/2026
Company Profile
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.